Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
OncoQR ML Logo
OncoQR ML CB Rank
672157
Heat Score
67
OncoQR ML is a pre-clinical biotech company that researches and develops novel adjustable cancel therapeutic cancer vaccines
Founded
obfuscation
Private Breitenfurt, Niederosterreich, Austria1-10 oncoqr.com/
Biotechnology
Health Care
Medical
Overview

OncoQR ML
Heat Score
67

Growth Score
pts
in past quarter
Heat Score 67
-11 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About OncoQR ML

CB Rank
672157
OncoQR ML is a pre-clinical biotech company that researches and develops novel adjustable cancel therapeutic cancer vaccines
Founded
obfuscation
Private Breitenfurt, Niederosterreich, Austria1-10 oncoqr.com/
Biotechnology
Health Care
Medical

Key People

  • Photo of Geert Mudde
    Geert Mudde: Founder and CSO
    Past Role: F-Star Therapeutics, CSO and Co-Founder

Details

Legal Name OncoQR ML GmbH
Operating Status Active
Company Type For Profit
Founders  Geert Mudde
Phone Number +43 1 230 60 0
Contact Email bd@oncoqr.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

S-TIR™ Platform
An adjustable cancer immunotherapy platform that enables the development of therapeutic cancer vaccines by targeting immune system checkpoints and activating tumor-specific immune responses.
OQR100 (TYG100)
A therapeutic cancer vaccine candidate targeting gastro-intestinal cancers by inducing neutralizing antibodies against gastrin to inhibit tumor growth.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 1

Employee Profiles

News
Technology
View Tech Report

IT Spend

$92.2KThis year, OncoQR ML is projected to spend $92.2K on IT, according to Aberdeen.

Active Website Tech Count

2OncoQR ML is actively using 2 technologies for its website, according to BuiltWith. These include Common Crawl and  CommonCrawl Top 50m.

Total IP

4The intellectual property of OncoQR ML includes 4 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is OncoQR ML's headquarters? OncoQR ML is located in Breitenfurt, Niederosterreich, Austria.Who are OncoQR ML's competitors? Alternatives and possible competitors to OncoQR ML may include OS Therapies, Agenus, and  OSE Immunotherapeutics.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(f8e1fc8 1)
|